Related Experiment Video

Updated: Jun 15, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Pharmacogenomics in drug induced liver injury

Raúl J Andrade1, José A G Agúndez, M Isabel Lucena

  • 1Hepatology Unit, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Málaga, Spain.

Current Drug Metabolism
|March 11, 2010
PubMed

Insights

Drug-induced liver injury (DILI) is a severe adverse effect. Genetic variations in drug metabolism, particularly CYP2E1, NAT2, and GSTM1, significantly influence DILI risk, necessitating further pharmacogenomic research.

Area of Science:

  • Pharmacogenomics
  • Hepatology
  • Drug Metabolism

Background:

  • Drug-induced liver injury (DILI) is a severe adverse effect with unpredictable, idiosyncratic cases.
  • Proposed mechanisms include reactive metabolites, immune responses, danger signals, and mitochondrial dysfunction.
  • Genetic variability in drug metabolism is a key factor in DILI susceptibility.

Purpose of the Study:

  • To review current knowledge on DILI mechanisms, clinical presentation, and risk factors.
  • To summarize pharmacogenomic evidence for DILI risk associated with drug-metabolizing enzyme gene polymorphisms.
  • To identify knowledge gaps and future research directions in DILI pharmacogenomics.

Main Methods:

  • Literature review of DILI mechanisms, clinical factors, and genetic associations.
  • Focused summary of pharmacogenomic studies on specific drug-metabolizing enzyme genes (CYP, NAT, GST, UGT).
  • Analysis of evidence strength for gene-DILI risk associations.

Main Results:

  • Conclusive associations between DILI risk and non-mutated CYP2E1, slow NAT2, and slow GSTM1 genotypes were found.
  • Polymorphisms in other studied genes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, GSTT1, UGTs) require further pharmacogenomic investigation.
  • Heterogeneity in existing studies presents challenges for definitive conclusions.

Conclusions:

  • Genetic factors, particularly specific genotypes of CYP2E1, NAT2, and GSTM1, play a conclusive role in DILI risk.
  • Further pharmacogenomic and toxicogenomic studies are essential to elucidate the genetic determinants of DILI.
  • Understanding these genetic factors is crucial for predicting and preventing DILI.

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...